Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fractyl Health (GUTS) Research & Development (2023 - 2025)

Fractyl Health (GUTS) has disclosed Research & Development for 3 consecutive years, with $17.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 8.14% year-over-year to $17.5 million, compared with a TTM value of $78.3 million through Sep 2025, up 29.77%, and an annual FY2024 reading of $70.5 million, up 85.26% over the prior year.
  • Research & Development was $17.5 million for Q3 2025 at Fractyl Health, down from $21.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $21.2 million in Q2 2025 and bottomed at $9.1 million in Q2 2023.
  • Average Research & Development over 3 years is $15.1 million, with a median of $16.8 million recorded in 2024.
  • The sharpest move saw Research & Development surged 102.56% in 2024, then decreased 8.14% in 2025.
  • Year by year, Research & Development stood at $10.2 million in 2023, then surged by 99.5% to $20.3 million in 2024, then dropped by 13.92% to $17.5 million in 2025.
  • Business Quant data shows Research & Development for GUTS at $17.5 million in Q3 2025, $21.2 million in Q2 2025, and $19.4 million in Q1 2025.